Keyphrases
Glioblastoma
100%
Immune Checkpoint Modulators
100%
Tumor
16%
Radiotherapy
16%
Clinical Development
16%
Patient Outcomes
16%
Clinical Data
16%
Ipilimumab
16%
Recurring
16%
Immune System
16%
Recurrent Disease
16%
Targeted Agents
16%
Conventional Therapy
16%
Overall Survival Time
16%
Treatment Strategy
16%
Potential Interaction
16%
Median Overall Survival
16%
Clinical Improvement
16%
Emerging Treatments
16%
Primary Brain Tumor
16%
Response Assessment
16%
Radiological Response
16%
Advanced Tumor
16%
Response Potential
16%
Temozolomide Chemotherapy
16%
Specific Properties
16%
Immune Checkpoint Inhibitors
16%
Nivolumab
16%
Pembrolizumab
16%
Immune Checkpoint Pathway
16%
Maximal Safe Resection
16%
Medicine and Dentistry
Glioblastoma
100%
Neoplasm
33%
Immunotherapy
33%
Radiation Therapy
16%
Recurrent Disease
16%
Surgery
16%
Ipilimumab
16%
Survival Time
16%
Overall Survival
16%
Immune System
16%
Brain Tumor
16%
Temozolomide
16%
Emerging Treatment
16%
Nivolumab
16%
Immune Checkpoint Inhibitor
16%
Pembrolizumab
16%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Neoplasm
33%
Immunotherapy
33%
Recurrent Disease
16%
Chemotherapy
16%
Ipilimumab
16%
Brain Tumor
16%
Overall Survival
16%
Preclinical Study
16%
Temozolomide
16%
Survival Time
16%
Nivolumab
16%
Immune Checkpoint Inhibitor
16%
Pembrolizumab
16%
Neuroscience
Ipilimumab
50%
Lambrolizumab
50%
Nivolumab
50%